Latest News

Robotic Assisted Urologic Laparoscopy

Impact of urology resident involvement on intraoperative, long-term oncologic and functional outcomes of robotic assisted laparoscopic radical prostatectomy.

To evaluate the impact of resident involvement in robot assisted laparascopic prostatectomy (RALP) on oncologic, functional, and intraoperative outcomes, both short and long term. We queried our prospectively maintained database of prostate cancer patients who underwent robotic-assisted laparoscopic prostatectomy from November 20, 2007 to December 27, 2016.

Robotic Assisted Urologic Laparoscopy

Impact of urology resident involvement on intraoperative, long-term oncologic and functional outcomes of robotic assisted laparoscopic radical prostatectomy.

To evaluate the impact of resident involvement in robot assisted laparascopic prostatectomy (RALP) on oncologic, functional, and intraoperative outcomes, both short and long term. We queried our prospectively maintained database of prostate cancer patients who underwent robotic-assisted laparoscopic prostatectomy from November 20, 2007 to December 27, 2016.

Robotic Assisted Urologic Laparoscopy

Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.

Radical cystectomy (RC) is the gold standard for non-metastatic muscle invasive bladder cancer, and for refractory non-muscle invasive disease. Compared to open RC, robot-assisted radical cystectomy (RARC) has been shown to provide comparable early oncologic outcomes and improved perioperative outcomes.

Uncategorized

Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer

PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS: Discovery and validation cohorts included patients who underwent mpMRI […]

Uncategorized

Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.

It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC). To update a previous preliminary series and investigate pathological outcomes for patients who failed to remain on AS. Prospective observational cohort study started in February 2008, and currently still active, […]

Uncategorized

Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.

Background: Danish guidelines on muscle invasive bladder cancer (MIBC) recommend neoadjuvant chemotherapy (NAC) for non-metastatic patients fit for cisplatin-based chemotherapy. The current indication is urothelial MIBC in patients less than 75 years old with no metastasis on imaging and normal renal function (GFR ≥ 60 ml/min). Data from the Danish Bladder Cancer Database (DaBlaCa-Data) reveals that […]

Uncategorized

Analysis of ceRNA network identifies prognostic circRNA biomarkers in bladder cancer.

Bladder cancer remains a very challenging disease to treat with the high rates of recurrence and progression associated with current therapies. Although the association between bladder cancer pathology and circRNAs remains undetermined, circRNAs signatures may be useful as prognostic and predictive factors and clinical tools for assessing disease state and outcome. This study investigates if […]

Uncategorized

DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome.

Advanced clear-cell renal-cell carcinoma (ccRCC), which is the most common subtype of kidney cancer, is considered to be lethal despite recent advancements in therapeutic agents. The benefit of adjuvant or neoadjuvant therapy with currently available agents remains controversial. We investigated the clinical implications of DNA damage response (DDR) pathway for locally advanced ccRCC. Localized ccRCC […]

Uncategorized

Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma.

Locally advanced and metastatic renal cell carcinoma (RCC) present a specific set of challenges to the radiologist. The detection of metastatic disease is confounded by the ability of RCC to metastasize to virtually any part of the human body long after surgical resection of the primary tumor. This includes sites not commonly included in routine […]

Uncategorized

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Nivolumab is standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because these patients were excluded from pivotal studies. We aimed to assess the activity of nivolumab in this population. The GETUG-AFU 26 NIVOREN phase II […]

X